

# STRESSED study.

Gepubliceerd: 04-08-2005 Laatste bijgewerkt: 18-08-2022

To investigate whether a strategy of direct stenting without pre-dilatation is associated with a reduced incidence of restenosis at 9 month follow-up angiography, compared to conventional stenting with pre-dilatation or compared to a strategy of...

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving gestart
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON25680

### Bron

NTR

### Verkorte titel

STRESSED

### Aandoening

Stable or unstable angina pectoris or a recent (<30 days) myocardial infarction with objective evidence of myocardial ischemia.

## Ondersteuning

**Primaire sponsor:** Dr AWJ van 't Hof  
Isala Klinieken, locatie Weezenlanden  
Department of Cardiology  
Groot Wezenland 20  
8011 JW Zwolle

## Onderzoeksproduct en/of interventie

## Uitkomstmaten

### Primaire uitkomstmaten

The primary end point is the mean minimal lumen diameter at follow-up angiography.

## Toelichting onderzoek

### Achtergrond van het onderzoek

#### Title:

**STRESSED study;  
direct Stenting To reduce REStenosis in Stent Era with Drug elution.**

#### Background:

Direct stenting (without pre-dilatation) has been shown to be a safe and effective treatment modality in elective patients as well as in patients who undergo angioplasty (PCI) because of unstable angina. Success rates vary from 90-98%. In most studies it has been shown to reduce procedure length, the use of contrast agent and the number of balloons and wires and therefore has been shown to reduce procedure related costs (1-8).

#### Objective:

To investigate whether a strategy of direct stenting without pre-dilatation is associated with a reduced incidence of restenosis at 9 month follow-up angiography, compared to conventional stenting with pre-dilatation or compared to a strategy of provisional stenting.

#### Design:

600 patients with stable or unstable angina, who are candidate for a PTCA, will be randomized to direct stenting, provisional stenting or pre dilatation.  
After 9 month a follow up angiogram will be made. After 24 month a follow-up will be done.

#### End Points:

##### Primary

The primary end point, is the so called 'Late Loss', defined as the difference in minimal lumen diameter between the first and the follow-up angiogram (derived from two orthogonal views (by the quantitative coronary angiography laboratory)).

##### Secondary

1. Clinical procedural success defined as angiographic success without major adverse cardiac events (MACE): death, myocardial infarction, or myocardial revascularization by repeat

angioplasty or coronary bypass surgery.

2. Rate of major adverse clinical events during the 9 and 24-month follow-up period.

### **Doel van het onderzoek**

To investigate whether a strategy of direct stenting without pre-dilatation is associated with a reduced incidence of restenosis at 9 month follow-up angiography, compared to conventional stenting with pre-dilatation or compared to a strategy of provisional stenting.

### **Onderzoeksproduct en/of interventie**

PCI:

Randomisation to Drug Eluted Stenting (DES) without (group Direct), with (group Conventional ) balloon predilatation or provisional stenting (group Provisional).

## **Contactpersonen**

### **Publiek**

Diagram B.V. Zwolle  
Dokter Stolteweg 96

J. Klijn  
Dokter Stolteweg 96

Zwolle 8025 AZ  
The Netherlands  
+31 (0)38 4262997

### **Wetenschappelijk**

Diagram B.V. Zwolle  
Dokter Stolteweg 96

J. Klijn  
Dokter Stolteweg 96

Zwolle 8025 AZ  
The Netherlands  
+31 (0)38 4262997

# Deelname eisen

## Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Men and Women less than 85 years of age;
2. Stable or unstable angina pectoris or a recent (<30 days) myocardial infarction with objective evidence of myocardial ischemia;
3. Lesion with > 50% and < 100% diameter stenosis according to the estimate of the investigator;
4. Single American College of Cardiology/American Heart Association (ACC/AHA) task force classification type A, B1 or B2 non-calcified target lesion;
5. No contraindication to inhibition of platelet function with aspirin and ticlopidine or clopidogrel.

## Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Acute ST elevation myocardial infarction;
2. Unstable angina pectoris, classified as Braunwald category IIIB or C;
3. Bifurcation lesions situated with a side branch > 2.0 mm in diameter;
4. Left main coronary artery lesions;
5. Ostial lesions;
6. Left ventricular ejection fraction of <30%;
7. Contra-indication for follow-up angiography (severe peripheral vessel disease, creatine-clearance < 30 ml/min).

## Onderzoeksopzet

### Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Blinding:	Open / niet geblindeerd
Controle:	Geneesmiddel

### Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	01-09-2005
Aantal proefpersonen:	600
Type:	Verwachte startdatum

## Ethische beoordeling

Positief advies	
Datum:	04-08-2005
Soort:	Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

## In overige registers

Register	ID
NTR-new	NL80
NTR-old	NTR111
Ander register	: N/A
ISRCTN	ISRCTN41213536

## Resultaten

### Samenvatting resultaten

1. Laarman G, Muthusamy TS, Swart H, Westendorp I, Kiemeneij F, Slagboom T, van der Wieken R. Direct coronary stent implantation: safety, feasibility, and predictors of success of the strategy of direct coronary stent implantation. *Catheter Cardiovasc Interv* 2001 Apr;52(4):443-448<br>
2. Le Breton H, Bosch J, Commeau P, Brunel P, Gilard M, Breut C, Bar O, Geslin P, Tirouvanziam A, Maillard L, Moquet B, Barragan P, Dupouy P, Grollier G, Berland J, Druelles P, Rihani R, Huret B, Leclercq C, Bedossa M. Randomised comparison of coronary stenting with and without balloon predilatation in selected patients. *Heart* 2001 Sep;86(3):302-308.<br>
3. Carrie D, Khalife K, Citron B, Izaaz K, Hamon M, Juiliard JM, Leclercq F, Fourcade J, Lipiecki J, Sabatier R, Boulet V, Rinaldi JP, Mourali S, Fatouch M, El Mokhtar E, Aboujaoude G, Elbaz M, Grolleau R, Steg PG, Puel J; Benefit Evaluation of Direct Coronary Stenting Study Group. Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris. BET (Benefit Evaluation of Direct Coronary Stenting) Study Group. *Am J Cardiol* 2001 Mar 15;87(6):693-698<br>
4. Taylor AJ, Broughton A, Federman J, Walton A, Keighley C, Haikerwal D, Krawczynszyn M, Shaw J, Goods C. Efficacy and safety of direct stenting in coronary angioplasty. *J Invasive Cardiol* 2000 Nov;12(11):560-565.<br>
5. Veselka J, Mates M, Tesar DB, Aschermann M, Urbanova T, Honek. Direct stenting without predilatation: a new approach to coronary intervention. *Coron Artery Dis* 2000 Sep;11(6):503-507.<br>
6. Ormiston JA, Webster MW, Ruygrok PN, Elliott JM, Simmonds MB, Meredith IT, Devlin GP, Stewart JT, Dixon SR, Price S, Ellis CJ, West TM. A randomized study of direct coronary stent delivery compared with stenting after predilatation: the NIR future trial. On behalf of the NIR Future Trial Investigators. *Catheter Cardiovasc Interv* 2000 Aug;50(4):377-381.<br>
7. de la Torre Hernandez JM, Gomez I, Rodriguez-Entem F, Zueco J, Figueroa A, Colman T. Evaluation of direct stent implantation without predilatation by intravascular ultrasound. *Am J Cardiol* 2000 Apr 15;85(8):1028-1030.<br>
8. Wilson SH, Berger PB, Mathew V, Bell MR, Garratt KN, Rihal CS, Bresnahan JF, Grill DE, Melby S, Holmes DR Jr. Immediate and late outcomes after direct stent implantation without balloon predilatation.. *J Am Coll Cardiol* 2000 Mar 15;35(4):937-943.<br>
9. PREDICT, Pre-dilatation vs. Direct stenting In Coronary Treatment, unpublished data.<br>
10. Sick PB, Woinke M, Lauer B, Gelbrich G, Schuler G. Angiographic long term results in coronary lesions after primary stenting in comparison with balloon dilatation followed by

stent implantation: a multifactorial ANOVA and regression analysis. *Circulation* 2001;1894(abstract).<br>

11. Foley DP, Pieper M, Wijns W, Suryapranata H, Grollier G, Legrand V, de Scheerder I, Hanet C, Puel J, Mudra H, Bonnier HJ, Colombo A, Thomas M, Probst P, Morice M, Kleijne J, Serruys PW; MAGIC 5L investigators. The influence of stent length on clinical and angiographic outcome in patients undergoing elective stenting for native coronary artery lesions; final results of the Magic 5L Study. *Eur Heart J* 2001;22:1585-93.<br>

12. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary Revascularization. *N Engl J Med.* 2002 Jun 6;346(23):1773-8.<br>

13. Grube E, Silber S, Hauptmann KE, Mueller R, Buellfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. *Circulation.* 2003 Jan 7;107(1):38-42.<br>

14. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. *Lancet.* 2004 Oct 23;364(9444):1519-21<br>

15. Niroomand F, Hauer O, Tiefenbacher CP, Katus HA, Kuebler W. Influence of alcohol consumption on restenosis rate after percutaneous transluminal coronary angioplasty and stent implantation. *Heart.* 2004 Oct;90(10):1189-93.